Analyzing MannKind Corporation (MNKD) and Its Peers
MannKind Corporation (NASDAQ: MNKD) is one of 297 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare MannKind Corporation to similar companies based on the strength of its earnings, institutional ownership, risk, dividends, profitability, analyst recommendations and valuation.
This is a breakdown of recent ratings and price targets for MannKind Corporation and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|MannKind Corporation Competitors||790||3130||11384||228||2.71|
MannKind Corporation currently has a consensus price target of $0.92, suggesting a potential downside of 71.50%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.86%. Given MannKind Corporation’s rivals stronger consensus rating and higher possible upside, analysts clearly believe MannKind Corporation has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
14.0% of MannKind Corporation shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 1.6% of MannKind Corporation shares are owned by insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares MannKind Corporation and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|MannKind Corporation||$174.76 million||$125.66 million||-11.89|
|MannKind Corporation Competitors||$290.00 million||$35.57 million||154.05|
MannKind Corporation’s rivals have higher revenue, but lower earnings than MannKind Corporation. MannKind Corporation is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
MannKind Corporation has a beta of 3.1, suggesting that its stock price is 210% more volatile than the S&P 500. Comparatively, MannKind Corporation’s rivals have a beta of 5.86, suggesting that their average stock price is 486% more volatile than the S&P 500.
This table compares MannKind Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|MannKind Corporation Competitors||-5,110.46%||-418.25%||-40.67%|
MannKind Corporation rivals beat MannKind Corporation on 9 of the 12 factors compared.
About MannKind Corporation
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.